Original Article

Changes in For-Profit Medication-Assisted Therapy Clinics in an Appalachian City

Authors: Hannah D. Holt, BS, Martin Olsen, MD

Abstract

Objectives: This study is a follow-up to previous research regarding buprenorphine medication-assisted therapy (MAT) in Johnson City, Tennessee. For-profit MAT clinics were surveyed to determine changes in tapering practice patterns and insurance coverage during the last 3 years.

Methods: Johnson City for-profit MAT clinics; also called office based opioid treatment centers, were surveyed by telephone. Clinic representatives were asked questions regarding patient costs for therapy, insurance coverage, counseling offered onsite, and opportunities for tapering while pregnant.

Results: All of the MAT clinics representatives indicated that tapering in pregnancy could be considered even though tapering in pregnancy is contrary to current national guidelines. Forty-three percent of the clinics now accept insurance as compared with 0% in the 2016 study. The average weekly cost per visit remained consistent.

Conclusions: The concept of tapering buprenorphine during pregnancy appears to have become a standard of care for this community, as representatives state it is offered at all of the clinics that were contacted. Representatives from three clinics stated the clinics require tapering, even though national organizations such as the American College of Obstetricians and Gynecologists and the American Society of Addiction Medicine do not recommend this approach. Although patients who have government or other insurance are now able to obtain buprenorphine with no expense at numerous clinics, the high cost for uninsured patients continues to create an environment conducive to buprenorphine diversion.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Alexander C, Breuel K, Olsen ME. High prevalence of buprenorphine in prenatal drug screens in an Appalachian city. South Med J 2020;113:111–115. 2. Nyakeriga AM, McDonald M. Neonatal abstinence syndrome surveillance annual report 2019. https://www.tn.gov/content/dam/tn/health/documents/nas/2019-NAS-Annual-Update.pdf. Published 2019. Accessed November 21, 2020. 3. Martin PR, Finlayson AJR. Opioid use disorder during pregnancy in Tennessee: expediency vs. science. Am J Drug Alcohol Abuse 2015;41:367–370. 4. Committee on Obstetric Practice. Committee Opinion No. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol 2017;130:e81–e94. 5. Monte AA, Mandell T, Wilford BB, et al. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis 2009;28:226–231. 6. Bell J, Towers CV, Hennessy MD, et al. Detoxification from opiate drugs during pregnancy. Am J Obstet Gynecol 2016;215:374e1–374.e6. 7. Olsen ME. Prevention of neonatal abstinence syndrome in an outpatient prenatal buprenorphine tapering program. South Med J 2020;113:553–558. 8. Jones HE, Dengler E, Garrison A, et al. Neonatal outcomes and their relationship to maternal buprenorphine dose during pregnancy. Drug Alcohol Depend 2014;134:414–417. 9. Dooley R, Dooley J, Antone I, et al. Narcotic tapering in pregnancy using long-acting morphine: an 18-month prospective cohort study in northwestern Ontario. Can Fam Physician 2015;61:e88–e95. 10. Walker JJ, Olsen ME. Provision of buprenorphine to pregnant women by for-profit clinics in an Appalachian city. South Med J 2018;111:575–578.